Zai Lab Ltd (ZLAB): Total Liabilities
$456.88M
As of 2025-12-31
$467.76M
As of 2026-06-30
+37.8%
3-year compound annual growth
+28.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $456.88M | +32.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $344.86M | +43.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $240.18M | +37.6% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $174.54M | -24.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $230.00M | +79.3% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $128.29M | +112.1% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $60.49M | +18.8% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $50.91M | +252.0% | 2020-04-29, Balance as of period end |
| 2017-12-31 | $14.46M | +143.0% | 2019-03-29, Balance as of period end |
| 2016-12-31 | $5.95M | n/a | 2018-04-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $3.01B | +26.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $528.12M | +18.6% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $2.15B | +5.0% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
Compare ZLAB, NATR, TVTX, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗